CM Management LLC Has $1.85 Million Stock Holdings in Jazz Pharmaceuticals plc (NASDAQ:JAZZ)

CM Management LLC decreased its stake in shares of Jazz Pharmaceuticals plc (NASDAQ:JAZZ - Free Report) by 25.0% during the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 15,000 shares of the specialty pharmaceutical company's stock after selling 5,000 shares during the quarter. CM Management LLC's holdings in Jazz Pharmaceuticals were worth $1,847,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. CIBC Asset Management Inc increased its holdings in shares of Jazz Pharmaceuticals by 5.2% during the fourth quarter. CIBC Asset Management Inc now owns 1,972 shares of the specialty pharmaceutical company's stock worth $243,000 after purchasing an additional 97 shares during the period. UMB Bank n.a. raised its position in shares of Jazz Pharmaceuticals by 70.9% during the fourth quarter. UMB Bank n.a. now owns 311 shares of the specialty pharmaceutical company's stock worth $38,000 after purchasing an additional 129 shares during the period. Jones Financial Companies Lllp boosted its holdings in Jazz Pharmaceuticals by 75.1% during the fourth quarter. Jones Financial Companies Lllp now owns 303 shares of the specialty pharmaceutical company's stock worth $37,000 after purchasing an additional 130 shares during the last quarter. Waterfront Wealth Inc. raised its stake in shares of Jazz Pharmaceuticals by 1.4% during the 4th quarter. Waterfront Wealth Inc. now owns 9,675 shares of the specialty pharmaceutical company's stock worth $1,191,000 after purchasing an additional 137 shares during the period. Finally, Ellsworth Advisors LLC boosted its stake in Jazz Pharmaceuticals by 0.4% in the fourth quarter. Ellsworth Advisors LLC now owns 37,962 shares of the specialty pharmaceutical company's stock valued at $4,675,000 after acquiring an additional 149 shares during the last quarter. 89.14% of the stock is owned by institutional investors.

Analyst Ratings Changes

JAZZ has been the subject of several recent analyst reports. HC Wainwright restated a "buy" rating and set a $200.00 target price on shares of Jazz Pharmaceuticals in a research report on Friday, November 22nd. Morgan Stanley reissued an "overweight" rating and issued a $183.00 price objective (up from $175.00) on shares of Jazz Pharmaceuticals in a research note on Friday. Robert W. Baird upped their target price on Jazz Pharmaceuticals from $154.00 to $162.00 and gave the company an "outperform" rating in a research note on Monday, November 18th. Cantor Fitzgerald cut shares of Jazz Pharmaceuticals from an "overweight" rating to a "neutral" rating and increased their target price for the company from $140.00 to $150.00 in a research report on Wednesday, February 26th. Finally, Royal Bank of Canada reduced their price target on Jazz Pharmaceuticals from $179.00 to $178.00 and set an "outperform" rating for the company in a research report on Wednesday, February 26th. One equities research analyst has rated the stock with a hold rating, fourteen have assigned a buy rating and one has given a strong buy rating to the company's stock. According to MarketBeat.com, the stock currently has a consensus rating of "Buy" and a consensus target price of $189.40.

Remove Ads

Insider Buying and Selling at Jazz Pharmaceuticals

In other Jazz Pharmaceuticals news, CEO Bruce C. Cozadd sold 1,500 shares of the stock in a transaction dated Monday, February 3rd. The shares were sold at an average price of $122.31, for a total transaction of $183,465.00. Following the sale, the chief executive officer now owns 439,744 shares of the company's stock, valued at $53,785,088.64. This represents a 0.34 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, EVP Neena M. Patil sold 3,800 shares of the stock in a transaction on Thursday, February 27th. The shares were sold at an average price of $144.87, for a total value of $550,506.00. Following the completion of the transaction, the executive vice president now owns 33,318 shares in the company, valued at $4,826,778.66. The trade was a 10.24 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 25,193 shares of company stock worth $3,533,122 over the last three months. Company insiders own 4.20% of the company's stock.

Jazz Pharmaceuticals Stock Up 1.7 %

Shares of JAZZ stock opened at $138.81 on Friday. The company has a debt-to-equity ratio of 1.46, a quick ratio of 3.74 and a current ratio of 4.26. Jazz Pharmaceuticals plc has a twelve month low of $99.06 and a twelve month high of $148.06. The stock's 50 day simple moving average is $128.14 and its 200 day simple moving average is $120.03. The company has a market capitalization of $8.43 billion, a price-to-earnings ratio of 19.55, a PEG ratio of 1.04 and a beta of 0.44.

About Jazz Pharmaceuticals

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.

Want to see what other hedge funds are holding JAZZ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Jazz Pharmaceuticals plc (NASDAQ:JAZZ - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.